Literature DB >> 32306406

Advanced forecasting of SARS-CoV-2-related deaths in Italy, Germany, Spain, and New York State.

Giovanni Sotgiu1, Alberto G Gerli2, Stefano Centanni3, Monica Miozzo4,5, G Walter Canonica6, Joan B Soriano7,8, J Christian Virchow9.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32306406      PMCID: PMC7264667          DOI: 10.1111/all.14327

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


× No keyword cloud information.
To the Editor, An appropriate forecasting model can contribute to define strategic choices both in limiting the spread of SARS‐Cov‐2 virus and in reducing the related mortality rate. Temporal trends of SARS‐CoV‐2 key epidemiological indicators (eg, mortality, incidence of infected cases) to describe the ongoing pandemic caused by SARS‐CoV‐2 have been estimated , , ; their accuracy is key to plan and implement adequate health interventions (eg, increasing ICU availability, distribute personal protection gear, an eventual vaccine). A number of studies tried to identify the best model to forecast SARS‐Cov‐2‐related deaths, interpolating daily cases according to a Gaussian curve. Recently, we suggested an innovative and robust data mining approach based on Chinese and Italian data to forecast SARS‐Cov‐2‐related mortality using a 3rd‐degree polynomial curve, which describes a growth up to the daily peak, and, then, a five parameter logistic (5PL) asymmetrical sigmoidal curve following a parametric growth (45% of aggregated cases at the peak day, which is at 20% of the estimated aggregated outbreak duration; 50% of total cases at 20.8% of the expected duration; 63.3% of total cases at 24% of the expected duration; 81.4% at 30% of the expected duration; 92.8% at 40% of the expected duration; 99.5% at 80% of the expected duration). Based on this, we derived a reliable model which was obtained by the analysis and interpolation of the aggregated cases since we do not expect a symmetric behavior of the curve after the daily peaks due to effect of different factors (eg, the social intervention, political measures, increase in ICU beds). Based on this model, we aimed at predicting SARS‐Cov‐2‐related mortality in Italy, Germany, Spain, and New York State. To validate the model, we calculated R2 correlations for Italy (0.995), Germany (0.996), Spain (0.988), and New York State (0.998) after 30, 18, 11, and 10 days of prediction, respectively, thus confirming the reliability of our modeling approach during the first month of this outbreak in each of these countries (Figure 1A).
Figure 1

A, The model accuracy curve is achieved using a 3rd‐grade polynomial curve in Italy, Germany, Spain, and New York State. It highlights the differences between real and simulated data after inputting the first 17 d. B, The curves depicting the predictions of the expected deaths are obtained by a 3rd‐grade polynomial curve up to daily peak and later by a parametric 5PL asymmetrical sigmoidal. The predictions are calculated starting from the first 17 d. The curve of expected deaths per country splits considering the number of days supposed to reach daily peak after the lockdown (28 d: upper curve; 21 d: lower curve)

A, The model accuracy curve is achieved using a 3rd‐grade polynomial curve in Italy, Germany, Spain, and New York State. It highlights the differences between real and simulated data after inputting the first 17 d. B, The curves depicting the predictions of the expected deaths are obtained by a 3rd‐grade polynomial curve up to daily peak and later by a parametric 5PL asymmetrical sigmoidal. The predictions are calculated starting from the first 17 d. The curve of expected deaths per country splits considering the number of days supposed to reach daily peak after the lockdown (28 d: upper curve; 21 d: lower curve) Accordingly, the expected number of SARS‐Cov‐2‐related deaths up to May 31, 2020, was associated with a curve suggesting no consistent correlation between the number of deaths and the size of the national population (Figure 1B). Instead, the expected SARS‐Cov‐2‐related mortality is more closely related to early events within the first days of the outbreak and to timing to regional/national interventions (eg, social distancing, confinement), which suggests that superspreading events (eg Lombardia region, Italy) deeply impact on the magnitude of the curve and, in turn, on the number of deaths. Importantly, the forecast is in keep with the number of days supposed to reach daily peak after the lockdown measures. Figure 1B illustrates the curves of the expected deaths based on daily peak after 28 and 21 days in Italy, Germany, Spain, and New York State. Based on this and provided current public health intervention remain unchanged, our model would predict by May 31st two different scenarios, high and low, for each country, specifically: Italy: a high of 50 562 ± 1264, and a low of 29 525 ± 738; Germany: a high of 11 400 ± 285, and a low of 5776 ± 144; Spain: a high of 54 867 ± 1372, and a low of 27 730 ± 693; and New York State: a high of 36 475 ± 912, and a low of 17 146 ± 429 of deaths. Taken together, these findings suggest that for both Italy and Spain, early superspreading events (eg, Codogno, a town located in Lombardia, and the Atalanta Bergamo vs FC Valencia football match in Milan on February 19th, Women's Day marches, Madrid, March 4th) have favored the increased number of deaths compared to Germany where such events occurred on a smaller scale (eg carnival, Heinsberg, Germany, February 15th, and the so‐called Westport soirée—Party Zero on March 5th, Westport, CT, USA). Despite being an advanced prediction, some limitations should be underscored, from an intrinsic wider uncertainty due to the fact that the underlying conditions can change to the possibility that interventions might be implemented based on such predictions, then changing the predicted outcome. We, therefore, recommend to carefully consider those estimates but with caution based on the above‐mentioned uncertainties. Our predictions were estimated for Italy, Germany, Spain, and New York State but can be translated to other settings. Based on this, it might also be possible to predict the number of respirators, health personnel needed and further spreading, downscaling, or healing curves but that would require additional data. For this purpose, positive cases would have to be monitored, for, for example, a 2‐week period and % of hospitalized and % of ICU patients assessed. These results, however, are heavily influenced by local factors such as the number of nondetected but infected patients, availability of hospital and ICU beds, local treatment protocols, and lack of prompt reporting of those recovered. The implications of our results highlight the key role of early spreading events during this SARS‐CoV‐2 pandemic and would call for rapid public health actions in future outbreaks.

CONFLICT OF INTEREST

Dr Virchow, Dr Soriano, Dr Canonica, Dr Miozzo, Dr Centanni, Dr Gerli, and Dr Sotgui have nothing to disclose.
  4 in total

1.  Predictive models for COVID-19-related deaths and infections.

Authors:  A G Gerli; S Centanni; M Miozzo; G Sotgiu
Journal:  Int J Tuberc Lung Dis       Date:  2020-06-01       Impact factor: 2.373

2.  Offline: COVID-19-what countries must do now.

Authors:  Richard Horton
Journal:  Lancet       Date:  2020-04-04       Impact factor: 79.321

3.  Monitoring the COVID-19 epidemic in the context of widespread local transmission.

Authors:  Alberto L García-Basteiro; Carlos Chaccour; Caterina Guinovart; Anna Llupià; Joe Brew; Antoni Trilla; Antoni Plasencia
Journal:  Lancet Respir Med       Date:  2020-04-02       Impact factor: 30.700

4.  Epidemiological data from the COVID-19 outbreak, real-time case information.

Authors:  Bo Xu; Bernardo Gutierrez; Sumiko Mekaru; Kara Sewalk; Lauren Goodwin; Alyssa Loskill; Emily L Cohn; Yulin Hswen; Sarah C Hill; Maria M Cobo; Alexander E Zarebski; Sabrina Li; Chieh-Hsi Wu; Erin Hulland; Julia D Morgan; Lin Wang; Katelynn O'Brien; Samuel V Scarpino; John S Brownstein; Oliver G Pybus; David M Pigott; Moritz U G Kraemer
Journal:  Sci Data       Date:  2020-03-24       Impact factor: 6.444

  4 in total
  15 in total

1.  Inflammation, underweight, malignancy and a marked catabolic state as predictors for worse outcomes in COVID-19 patients with moderate-to-severe disease admitted to Internal Medicine Unit.

Authors:  Valeria Guglielmi; Luca Colangeli; Valeria Scipione; Simona Ballacci; Martina Di Stefano; Lauren Hauser; Michela Colella Bisogno; Monica D'Adamo; Emanuela Medda; Paolo Sbraccia
Journal:  PLoS One       Date:  2022-05-18       Impact factor: 3.752

2.  Inpatient Care during the COVID-19 Pandemic: A Survey of Italian Physicians.

Authors:  Marina Attanasi; Simone Pasini; Antonio Caronni; Giulia Michela Pellegrino; Paola Faverio; Sabrina Di Pillo; Matteo Maria Cimino; Giuseppe Cipolla; Francesco Chiarelli; Stefano Centanni; Giuseppe Francesco Sferrazza Papa
Journal:  Respiration       Date:  2020-08-05       Impact factor: 3.580

3.  Estimating the Prevalence and Mortality of Coronavirus Disease 2019 (COVID-19) in the USA, the UK, Russia, and India.

Authors:  Yongbin Wang; Chunjie Xu; Sanqiao Yao; Yingzheng Zhao; Yuchun Li; Lei Wang; Xiangmei Zhao
Journal:  Infect Drug Resist       Date:  2020-09-29       Impact factor: 4.003

Review 4.  A compendium answering 150 questions on COVID-19 and SARS-CoV-2.

Authors:  Carmen Riggioni; Pasquale Comberiati; Mattia Giovannini; Ioana Agache; Mübeccel Akdis; Magna Alves-Correia; Josep M Antó; Alessandra Arcolaci; Ahmet Kursat Azkur; Dilek Azkur; Burcin Beken; Cristina Boccabella; Jean Bousquet; Heimo Breiteneder; Daniela Carvalho; Leticia De Las Vecillas; Zuzana Diamant; Ibon Eguiluz-Gracia; Thomas Eiwegger; Stefanie Eyerich; Wytske Fokkens; Ya-Dong Gao; Farah Hannachi; Sebastian L Johnston; Marek Jutel; Aspasia Karavelia; Ludger Klimek; Beatriz Moya; Kari C Nadeau; Robyn O'Hehir; Liam O'Mahony; Oliver Pfaar; Marek Sanak; Jürgen Schwarze; Milena Sokolowska; María J Torres; Willem van de Veen; Menno C van Zelm; De Yun Wang; Luo Zhang; Rodrigo Jiménez-Saiz; Cezmi A Akdis
Journal:  Allergy       Date:  2020-07-20       Impact factor: 14.710

Review 5.  Immunology of COVID-19: Mechanisms, clinical outcome, diagnostics, and perspectives-A report of the European Academy of Allergy and Clinical Immunology (EAACI).

Authors:  Milena Sokolowska; Zuzanna M Lukasik; Ioana Agache; Cezmi A Akdis; Deniz Akdis; Mübeccel Akdis; Weronika Barcik; Helen A Brough; Thomas Eiwegger; Andrzej Eljaszewicz; Stefanie Eyerich; Wojciech Feleszko; Cristina Gomez-Casado; Karin Hoffmann-Sommergruber; Jozef Janda; Rodrigo Jiménez-Saiz; Marek Jutel; Edward F Knol; Inge Kortekaas Krohn; Akash Kothari; Joanna Makowska; Marcin Moniuszko; Hideaki Morita; Liam O'Mahony; Kari Nadeau; Cevdet Ozdemir; Isabella Pali-Schöll; Oscar Palomares; Francesco Papaleo; Mary Prunicki; Carsten B Schmidt-Weber; Anna Sediva; Jürgen Schwarze; Mohamed H Shamji; Gerdien A Tramper-Stranders; Willem van de Veen; Eva Untersmayr
Journal:  Allergy       Date:  2020-10       Impact factor: 14.710

6.  COVID-19: A series of important recent clinical and laboratory reports in immunology and pathogenesis of SARS-CoV-2 infection and care of allergy patients.

Authors:  Oliver Pfaar; Maria J Torres; Cezmi A Akdis
Journal:  Allergy       Date:  2021-03       Impact factor: 14.710

7.  Forecasting efforts from prior epidemics and COVID-19 predictions.

Authors:  Pranay Nadella; Akshay Swaminathan; S V Subramanian
Journal:  Eur J Epidemiol       Date:  2020-07-17       Impact factor: 8.082

8.  Epidemiology of COVID-19 and Predictors of Recovery in the Republic of Korea.

Authors:  Ashis Kumar Das; Saji Saraswathy Gopalan
Journal:  Pulm Med       Date:  2020-07-30

9.  Asthma and COVID-19: Is asthma a risk factor for severe outcomes?

Authors:  Sebastian L Johnston
Journal:  Allergy       Date:  2020-07       Impact factor: 14.710

10.  COVID-19 pandemic: Practical considerations on the organization of an allergy clinic-An EAACI/ARIA Position Paper.

Authors:  Oliver Pfaar; Ludger Klimek; Marek Jutel; Cezmi A Akdis; Jean Bousquet; Heimo Breiteneder; Sharon Chinthrajah; Zuzana Diamant; Thomas Eiwegger; Wytske J Fokkens; Hans-Walter Fritsch; Kari C Nadeau; Robyn E O'Hehir; Liam O'Mahony; Winfried Rief; Vanitha Sampath; Manfred Schedlowski; María José Torres; Claudia Traidl-Hoffmann; De Yun Wang; Luo Zhang; Matteo Bonini; Randolf Brehler; Helen Annaruth Brough; Tomás Chivato; Stefano R Del Giacco; Stephanie Dramburg; Radoslaw Gawlik; Aslı Gelincik; Karin Hoffmann-Sommergruber; Valerie Hox; Edward F Knol; Antti Lauerma; Paolo M Matricardi; Charlotte G Mortz; Markus Ollert; Oscar Palomares; Carmen Riggioni; Jürgen Schwarze; Isabel Skypala; Eva Untersmayr; Jolanta Walusiak-Skorupa; Ignacio J Ansotegui; Claus Bachert; Anna Bedbrook; Sinthia Bosnic-Anticevich; Luisa Brussino; Giorgio Walter Canonica; Victoria Cardona; Pedro Carreiro-Martins; Alvaro A Cruz; Wienczyslawa Czarlewski; João A Fonseca; Maia Gotua; Tari Haahtela; Juan Carlos Ivancevich; Piotr Kuna; Violeta Kvedariene; Désirée Erlinda Larenas-Linnemann; Amir Hamzah Abdul Latiff; Mika Mäkelä; Mário Morais-Almeida; Joaquim Mullol; Robert Naclerio; Ken Ohta; Yoshitaka Okamoto; Gabrielle L Onorato; Nikolaos G Papadopoulos; Vincenzo Patella; Frederico S Regateiro; Bolesław Samoliński; Charlotte Suppli Ulrik; Sanna Toppila-Salmi; Arunas Valiulis; Maria-Teresa Ventura; Arzu Yorgancioglu; Torsten Zuberbier; Ioana Agache
Journal:  Allergy       Date:  2021-03       Impact factor: 14.710

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.